OOIR: Observatory of International Research

Papers

(The H4-Index of Molecular Cancer is 106. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Correction: m6A demethylase ALKBH5 inhibits tumor growth and metastasis by reducing YTHDFs-mediated YAP expression and inhibiting miR-107/LATS2–mediated YAP activity in NSCLC	1196
LMTK3 regulation of EV biogenesis and cargo sorting promotes tumour growth by reducing monocyte infiltration and driving pro-tumourigenic macrophage polarisation in breast cancer	1018
Polyamine and EIF5A hypusination downstream of c-Myc confers targeted therapy resistance in BRAF mutant melanoma	985
Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers	761
Traditional Chinese medicine for the treatment of cancers of hepatobiliary system: from clinical evidence to drug discovery	717
The miR-23a/27a/24 − 2 cluster drives immune evasion and resistance to PD-1/PD-L1 blockade in non-small cell lung cancer	709
CRISPR based therapeutics: a new paradigm in cancer precision medicine	638
TGF-β signaling promotes cervical cancer metastasis via CDR1as	614
The epigenetic regulatory mechanism of PIWI/piRNAs in human cancers	586
The CD47/TSP-1 axis: a promising avenue for ovarian cancer treatment and biomarker research	583
Intercellular TIMP-1-CD63 signaling directs the evolution of immune escape and metastasis in KRAS-mutated pancreatic cancer cells	565
BRD9-p53-E2F1 circuit orchestrates cell growth and DNA damage repair in gastric cancer	540
Engineered multifunctional nanoparticles for enhanced radiation therapy: three-in-one approach for cancer treatment	532
LINC02159 promotes non-small cell lung cancer progression via ALYREF/YAP1 signaling	453
Correction to: The function and mechanisms of action of circular RNAs in Urologic Cancer	414
Advances in RNA-based cancer therapeutics: pre-clinical and clinical implications	381
Chaperone-mediated autophagy modulates Snail protein stability: implications for breast cancer metastasis	341
ERK mediates interferon gamma-induced melanoma cell death	325
Proteogenomic characterization of molecular and cellular targets for treatment-resistant subtypes in locally advanced cervical cancers	319
Immunotherapies in rare cancers	318
The construction of modular universal chimeric antigen receptor T (MU-CAR-T) cells by covalent linkage of allogeneic T cells and various antibody fragments	309
Exosomal circSIPA1L3-mediated intercellular communication contributes to glucose metabolic reprogramming and progression of triple negative breast cancer	307
Genome-wide CRISPR screening identifies tyrosylprotein sulfotransferase-2 as a target for augmenting anti-PD1 efficacy	300
Integrative gene network and functional analyses identify a prognostically relevant key regulator of metastasis in Ewing sarcoma	289
The circular RNA circHMGB2 drives immunosuppression and anti-PD-1 resistance in lung adenocarcinomas and squamous cell carcinomas via the miR-181a-5p/CARM1 axis	285

JUN mediates the senescence associated secretory phenotype and immune cell recruitment to prevent prostate cancer progression	263
EWSR1-induced circNEIL3 promotes glioma progression and exosome-mediated macrophage immunosuppressive polarization via stabilizing IGF2BP3	255
circNOX4 activates an inflammatory fibroblast niche to promote tumor growth and metastasis in NSCLC via FAP/IL-6 axis	251
STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway	250
E3 ubiquitin ligase MAGI3 degrades c-Myc and acts as a predictor for chemotherapy response in colorectal cancer	247
Correction: Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p/snail/DPP4 axis	234
A bispecific Clec9A-PD-L1 targeted type I interferon profoundly reshapes the tumor microenvironment towards an antitumor state	228
Correction: YTHDF2 in peritumoral hepatocytes mediates chemotherapy-induced antitumor immune responses through CX3CL1-mediated CD8+ T cell recruitment	224
Tumor cell-intrinsic MELK enhanced CCL2-dependent immunosuppression to exacerbate hepatocarcinogenesis and confer resistance of HCC to radiotherapy	223
Nuclear receptors as novel regulators that modulate cancer radiosensitivity and normal tissue radiotoxicity	222
Bidirectional role of neutrophils in tumor development	222
KMT2C methyltransferase domain regulated INK4A expression suppresses prostate cancer metastasis	212
Biomolecular phase separation in tumorigenesis: from aberrant condensates to therapeutic vulnerabilities	199
Nanomedicine in Cancer Therapeutics: Current Perspectives from Bench to Bedside	195
Effects of RNA methylation on Tumor angiogenesis and cancer progression	193
Biofilm formation by the host microbiota: a protective shield against immunity and its implication in cancer	193
Efferocytosis: the art of cellular clearance and novel perspectives in disease therapy	191
NK cells are never alone: crosstalk and communication in tumour microenvironments	184
LINC00115 promotes chemoresistant breast cancer stem-like cell stemness and metastasis through SETDB1/PLK3/HIF1α signaling	184
PIK3CA mutations-mediated downregulation of circLHFPL2 inhibits colorectal cancer progression via upregulating PTEN	181
Therapy-induced senescent tumor cell-derived extracellular vesicles promote colorectal cancer progression through SERPINE1-mediated NF-κB p65 nuclear translocation	178
Myofibroblast-derived extracellular vesicles facilitate cancer stemness of hepatocellular carcinoma via transferring ITGA5 to tumor cells	174
Gold nanoparticles and gold nanorods in the landscape of cancer therapy	166
Molecular mechanisms and therapeutic significance of Tryptophan Metabolism and signaling in cancer	166
Insights into N6-methyladenosine and programmed cell death in cancer	166
Nanotechnology-leveraged CRISPR/Cas systems: icebreaking in trace cancer-related nucleic acids biosensing	163
Emerging roles of tRNA-derived fragments in cancer	163
Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments	161
Nasopharyngeal carcinoma: current views on the tumor microenvironment's impact on drug resistance and clinical outcomes	159
Letter to the Editor: An ultra-sensitive assay using cell-free DNA fragmentomics for multi-cancer early detection	157
Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer	155
Biologically targeted dual adaptive and innate nano-Immunotherapy for clear cell renal cell carcinoma treatment	154
CircAKT3 promotes prostate cancer proliferation and metastasis by enhancing the binding of RPS27A and RPL11	152
Correction: Circular RNA-encoded oncogenic PIAS1 variant blocks immunogenic ferroptosis by modulating the balance between SUMOylation and phosphorylation of STAT1	152
Deubiquitination of CDC6 by OTUD6A promotes tumour progression and chemoresistance	152
Dissecting small cell carcinoma of the esophagus ecosystem by single-cell transcriptomic analysis	149
Retraction Note: Tetrathiomolybdate inhibits head and neck cancer metastasis by decreasing tumor cell motility, invasiveness and by promoting tumor cell anoikis	149
Tumor-associated macrophages: untapped molecular targets to improve T cell-based immunotherapy	149
Loss of TACC2 impairs chemokine CCL3 and CCL4 expression and reduces response to anti-PD-1 therapy in soft tissue sarcoma	145
The application of organoids in treatment decision-making for digestive system cancers: progress and challenges	141
lncRNAs: the unexpected link between protein synthesis and cancer adaptation	141
Capmatinib is an effective treatment for MET-fusion driven pediatric high-grade glioma and synergizes with radiotherapy	140
The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancer	139
Identification of multidrug chemoresistant genes in head and neck squamous cell carcinoma cells	139
A positive feedback loop between PFKP and c-Myc drives head and neck squamous cell carcinoma progression	138
Enhancing therapeutic anti-cancer responses by combining immune checkpoint and tyrosine kinase inhibition	138
Correction: CircSMARCC1 facilitates tumor progression by disrupting the crosstalk between prostate cancer cells and tumor-associated macrophages via miR-1322/CCL20/CCR6 signaling	137
Context-dependent impact of type I interferon signaling in cancer	135
A non-coding RNA balancing act: miR-346-induced DNA damage is limited by the long non-coding RNA NORAD in prostate cancer	134
Liquid biopsy in lung cancer: significance in diagnostics, prediction, and treatment monitoring	132

Neuroscience of cancer: unraveling the complex interplay between the nervous system, the tumor and the tumor immune microenvironment	130
Crosstalk between autophagy and microbiota in cancer progression	129
m6A methylation reader IGF2BP2 activates endothelial cells to promote angiogenesis and metastasis of lung adenocarcinoma	128
Circular RNA circCLASP2 promotes nasopharyngeal carcinoma progression through binding to DHX9 to enhance PCMT1 translation	126
Acidosis-mediated increase in IFN-γ-induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumors	124
Functional CRISPR screens in T cells reveal new opportunities for cancer immunotherapies	124
Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing	123
Comprehensive characterization of the prostate tumor microenvironment identifies CXCR4/CXCL12 crosstalk as a novel antiangiogenic therapeutic target in prostate cancer	122
Molecular mechanisms of tumor resistance to radiotherapy	121
Exosome circATP8A1 induces macrophage M2 polarization by regulating the miR-1-3p/STAT6 axis to promote gastric cancer progression	119
DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy	117
Long non-coding RNA NORAD/miR-224-3p/MTDH axis contributes to CDDP resistance of esophageal squamous cell carcinoma by promoting nuclear accumulation of β-catenin	116
EMT/MET plasticity in cancer and Go-or-Grow decisions in quiescence: the two sides of the same coin?	115
Distinct pattern of genomic breakpoints in CML and BCR::ABL1-positive ALL: analysis of 971 patients	114
Correction: Long non-coding RNA GBCDRlnc1 induces chemoresistance of gallbladder cancer cells by activating autophagy	114
Size matters: integrating tumour volume and immune activation signatures predicts immunotherapy response	114
Correction: MIR22HG acts as a tumor suppressor via TGFβ/SMAD signaling and facilitates immunotherapy in colorectal cancer	114
Activation-induced cytidine deaminase causes recurrent splicing mutations in diffuse large B-cell lymphoma	114
Targeting HNRNPU to overcome cisplatin resistance in bladder cancer	114
Harnessing the MYB-dependent TAL1 5’super-enhancer for targeted therapy in T-ALL	113
OLFM4 promotes the progression of intestinal metaplasia through activation of the MYH9/GSK3β/β-catenin pathway	112
Multimodal sequencing of neoadjuvant nivolumab treatment in hepatocellular carcinoma reveals cellular and molecular immune landscape for drug response	112
Deciphering a profiling based on multiple post-translational modifications functionally associated regulatory patterns and therapeutic opportunities in human hepatocellular carcinoma	112
Metabolic checkpoints in immune cell reprogramming: rewiring immunometabolism for cancer therapy	111
N-glycosylation of PD-L1 modulates the efficacy of immune checkpoint blockades targeting PD-L1 and PD-1	111
Targeting metastasis in paediatric bone sarcomas	110
Cancer neuroscience in head and neck: interactions, modulation, and therapeutic strategies	110
The circROBO1/KLF5/FUS feedback loop regulates the liver metastasis of breast cancer by inhibiting the selective autophagy of afadin	108
CircSMARCC1 facilitates tumor progression by disrupting the crosstalk between prostate cancer cells and tumor-associated macrophages via miR-1322/CCL20/CCR6 signaling	106
An exosome-based liquid biopsy signature for pre-operative identification of lymph node metastasis in patients with pathological high-risk T1 colorectal cancer	106
Hypoxia-induced lncRNA STEAP3-AS1 activates Wnt/β-catenin signaling to promote colorectal cancer progression by preventing m6A-mediated degradation of STEAP3 mRNA	106